Safety and efficacy of ombitasvir/paritaprevir/ritonavir in genotype 1b-infected elderly Japanese patients in the GIFT-I study

In this post hoc analysis of GIFT-I, we report on the efficacy and safety of the 12-week ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) regimen in Japanese patients ≥70 or

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Kanzo 2017/07/20, Vol.58(7), pp.386-392
Hauptverfasser:	Chayama, Kazuaki, Karino, Yoshiyasu, Rodrigues, Lino, Jr, Burroughs, Margaret H, Pilot-Matias, Tami, Zhang, Xinyan, Kapoor, Mudra, Kumada, Hiromitsu
Format:	Artikel
Sprache:	eng ; jpn
Schlagworte:	elderly patients genotype 1b hepatitis C ombitasvir/paritaprevir/ritonavir phase 3 trial safety/efficacy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this post hoc analysis of GIFT-I, we report on the efficacy and safety of the 12-week ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) regimen in Japanese patients ≥70 or
ISSN:	0451-4203 1881-3593
DOI:	10.2957/kanzo.58.386